Physician profile
Gussie Bell Branch
NPI 1003263559
$1,814.19
in general payments reported to CMS, 2019-2025
14 companies · $805 in 2025
The $805 reported for 2025 was more than what 87% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $280 · 2020: $102 · 2021: $60.06 · 2022: $180 · 2023: $71.94 · 2024: $316 · 2025: $805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,192.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $434.53 | 2019-2025 | |
| Johnson & Johnson Vision Care, INC. | $322.08 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $236.70 | 2024-2025 | Arise, Infuse |
| Tarsus Pharmaceuticals, INC. | $201.63 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $183.78 | 2024-2025 | Ce-Marked Kxla System, Photrexa Viscous and Photrexa |
| Alcon Vision LLC | $151.76 | 2019-2025 | Rocklatan, Simbrinza, Rhopressa |
| Dompe US, INC. | $80.26 | 2025 | Oxervate |
| Shire North American Group INC | $65.96 | 2019 | |
| Abbvie INC. | $33.55 | 2025 | |
| Novartis Pharmaceuticals Corporation | $29.41 | 2021 | |
| Allergan, INC. | $26.16 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Coopervision INC. | $16.53 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $12.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gussie Branch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.